Abstract
Purpose:
Patients with prostate cancer who have biochemical recurrence after curative therapy are at higher risk for distant metastasis and cancer specific death. Assessment of aberrant DNA methylation in urine might complement currently used clinical prognostic factors and serve as a noninvasive tool for early prediction of biochemical recurrence after radical prostatectomy.
Materials and Methods:
Promoter methylation of 7 genes was evaluated by methylation sensitive polymerase chain reaction in 149 prostate cancer tissues, 37 noncancerous prostate tissues and 17 benign prostatic hyperplasia samples. Quantitative polymerase chain reaction was used for DNA methylation analysis of the urine of 253 patients with prostate cancer and 32 with benign prostatic hyperplasia.
Results:
In prostate cancer tissue the most frequently methylated genes were RASSF1, GSTP1 and RARB, which combined were positively identified in 85% of cases. These genes were also methylated in the urine of 60% of patients with prostate cancer. RASSF1 was methylated in 45% of prostate cancer urine samples with methylation intensity significantly higher in prostate cancer than in benign prostatic hyperplasia cases (p = 0.018). In a univariate model RASSF1 methylation and the total number of methylated genes in prostate cancer tissue were predictive of time to biochemical recurrence (p = 0.019 and 0.043, respectively). On multivariate analysis RASSF1 methylation together with pathological stage was the most significant predictor of biochemical recurrence in patients with Gleason score 6 tumors when analyzed in tissue and urine (p ≤0.001).
Conclusions:
Hypermethylation of RASSF1 in cancerous tissue and urine from patients with prostate cancer correlated with biochemical recurrence after radical prostatectomy. The prognostic potential of this biomarker deserves further investigation.
References
- 1 : Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer2013; 49: 1374. Google Scholar
- 2 : Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol2004; 172: 910. Link, Google Scholar
- 3 : The genomic landscape of prostate cancer. Int J Mol Sci2013; 14: 10822. Google Scholar
- 4 : Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol2013; 63: 920. Google Scholar
- 5 : Methylated genes as potential biomarkers in prostate cancer. BJU Int2010; 105: 1364. Google Scholar
- 6 : A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res2004; 10: 8472. Google Scholar
- 7 : Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol2004; 202: 233. Google Scholar
- 8 : Towards the detection of prostate cancer in urine: a critical analysis. J Urol2013; 189: 422. Link, Google Scholar
- 9 : Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology2008; 75: 145. Google Scholar
- 10 : Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res2002; 8: 514. Google Scholar
- 11 : Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res2004; 64: 1975. Google Scholar
- 12 : CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology2008; 71: 161. Google Scholar
- 13 : DNA hypermethylation status of multiple genes in prostate adenocarcinomas. Jpn J Cancer Res2002; 93: 767. Google Scholar
- 14 : DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol2012; 31: 187. Google Scholar
- 15 : Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res2005; 11: 8321. Google Scholar
- 16 : Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol2007; 51: 665. Google Scholar
- 17 : Association of tissue promoter methylation levels of APC, TGFB2, HOXD3 and RASSF1 with prostate cancer progression. Int J Cancer2011; 129: 2454. Google Scholar
- 18 : Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol2005; 23: 6569. Google Scholar
- 19 : Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res2007; 13: 1720. Google Scholar
- 20 : DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate2009; 69: 1257. Google Scholar
- 21 : Measurement of GSTP1 promoter methylation in bodily fluids may complement PSA screening: a meta-analysis. Br J Cancer2011; 105: 65. Google Scholar
- 22 : Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control2013; 24: 1615. Google Scholar
